Mediobanca nearly nine times subscribed for rare T2

© 2025 GlobalCapital, Derivia Intelligence Limited, company number 15235970, 4 Bouverie Street, London, EC4Y 8AX. Part of the Delinian group. All rights reserved.

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement | Event Participant Terms & Conditions

Mediobanca nearly nine times subscribed for rare T2

Moderna_PA_575x375_161120
In this photo illustration the medical syringe is seen with Moderna Therapeutics company logo displayed on a screen in the background (Photo by Rafael Henrique / SOPA Images/Sipa USA) | SOPA Images/SIPA USA/PA Images

Mediobanca was swamped with orders for a small tier two on Monday, as investors welcomed a rare opportunity to gain subordinated exposure to the Italian bank. Its deal was further supported by another positive development in the race to roll out a vaccine for Covid-19.

Unlock this article.

The content you are trying to view is exclusive to our subscribers.

To unlock this article:

Request a Free Trial or Login
Gift this article